Skip to Content
Merck
CN

Key Documents

View All Documentation

R9156

Raltitrexed

≥98% (HPLC), solid

Synonym(s):

L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl), ICI-D-1694, ZD-1694

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C21H22N4O6S
CAS Number:
112887-68-0
Molecular Weight:
458.49
UNSPSC Code:
12352200
PubChem Substance ID:
329824044
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

off-white to light yellow

solubility

H2O: ≥10 mg/mL, DMSO: ≥40 mg/mL

originator

AstraZeneca

storage temp.

2-8°C

SMILES string

O=C1NC(C)=NC2=C1C=C(CN(C3=CC=C(C(N[C@H](CCC(O)=O)C(O)=O)=O)S3)C)C=C2

Biochem/physiol Actions

Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives.
Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives. By inhibiting the formation of precursor pyrimidine nucleotides, raltitrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

hcodes

H300,H360

Hazard Classifications

Acute Tox. 2 Oral - Repr. 1B

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000465216
0000465216
0000062720
0000050063

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Folic Acid Metabolism in Cancer

Cancer research innovations address the complexity of the disease, providing advanced technologies for varied applications.

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Bioactive Molecules for Apoptosis

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

View All Articles
Helena Almqvist et al.
Nature communications, 7, 11040-11040 (2016-03-25)
Target engagement is a critical factor for therapeutic efficacy. Assessment of compound binding to native target proteins in live cells is therefore highly desirable in all stages of drug discovery. We report here the first compound library screen based on
Ken Yamashita et al.
Cancer science, 111(7), 2431-2439 (2020-05-18)
MYCN gene amplification is consistently associated with poor prognosis in patients with neuroblastoma, a pediatric tumor arising from the sympathetic nervous system. Conventional anticancer drugs, such as alkylating agents and platinum compounds, have been used for the treatment of high-risk

Global Trade Item Number

SKUGTIN
R9156-10MG04061833221204
R9156-50MG04061833221211